Biomarkers for pediatric urological disease

Current Opinion in Urology

Volumn 19, Issue 4, 2009, Pages 397-401

  Lee, Richard S ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Biomarker; Proteomics; Renal obstruction; Urinary proteome; Vesicoureteral reflux

Indexed keywords

ALPHA 1 MICROGLOBULIN; ALPHA FETOPROTEIN; BASIC FIBROBLAST GROWTH FACTOR; BIOLOGICAL MARKER; CHORIONIC GONADOTROPIN BETA SUBUNIT; CREATININE; CYSTATIN C; ENDOTHELIN 1; EPIDERMAL GROWTH FACTOR; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GELATINASE B; INTERLEUKIN 18; INTERLEUKIN 8; KIDNEY INJURY MOLECULE 1; LACTATE DEHYDROGENASE; LAMININ; MONOCYTE CHEMOTACTIC PROTEIN 1; N ACETYL BETA GLUCOSAMINIDASE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PROCALCITONIN; PROSTATE SPECIFIC ANTIGEN; SCATTER FACTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA1; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

ACUTE PYELONEPHRITIS; BLADDER CARCINOMA; CLINICAL STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DIAGNOSTIC PROCEDURE; DISEASE CLASSIFICATION; ENZYME BLOOD LEVEL; FOCAL GLOMERULOSCLEROSIS; HUMAN; HYDRONEPHROSIS; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY CARCINOMA; KIDNEY INJURY; KIDNEY SCAR; MEDICAL LITERATURE; MONITORING; NONHUMAN; PEDIATRICS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEOMICS; PYELONEPHRITIS; REVIEW; RISK; TESTIS CANCER; URETEROPELVIC JUNCTION OBSTRUCTION; URINARY TRACT DISEASE; UROLOGY; VALIDATION STUDY; VESICOURETERAL REFLUX;

ADOLESCENT; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; INFANT, NEWBORN; PROTEOMICS; URETERAL OBSTRUCTION; UROLOGIC DISEASES; VESICO-URETERAL REFLUX;

EID: 68249120137     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOU.0b013e32832c90ec     Document Type: Review

References (49)

1. LaBaer J. So, you want to look for biomarkers (introduction to the special biomarkers issue). J Proteome Res 2005; 4:1053-1059. (Pubitemid 41208663)
2. Bast RC Jr, Ravdin P, Hayes DF, et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19:1865-1878. (Pubitemid 32230890)
3. Ward JF, Moul JW. Rising prostate-specific antigen after primary prostate cancer therapy. Nat Clin Prac 2005; 2:174-182. (Pubitemid 40823138)
4. Rowland RG. Serum markers in testicular germ-cell neoplasms. Hematol Oncol Clin N Am 1988; 2:485-489. (Pubitemid 18236126)
5. Freedman AL, Bukowski TP, Smith CA, et al. Use of urinary beta-2-microglobulin to predict severe renal damage in fetal obstructive uropathy. Fetal Diagn Ther 1997; 12:1-6.
6. Freedman AL, Bukowski TP, Smith CA, et al. Fetal therapy for obstructive uropathy: diagnosis specific outcomes [corrected]. J Urol 1996; 156:720-723; discussion 723-724.
7. Johnson MP, Bukowski TP, Reitleman C, et al. In utero surgical treatment of fetal obstructive uropathy: a new comprehensive approach to identify appropriate candidates for vesicoamniotic shunt therapy. Am J Obstet Gynecol 1994; 170:1770-1776; discussion 1776-1779.
8. Lim GY, Jang HS, Lee EJ, et al. Utility of the resistance index ratio in differentiating obstructive from nonobstructive hydronephrosis in children. J Clin Ultrasound 1999; 27:187-193.
9. Rawashdeh YF, Djurhuus JC, Mortensen J, et al. The intrarenal resistive index as a pathophysiological marker of obstructive uropathy. J Urol 2001; 165:1397-1404. (Pubitemid 32410203)
10. Hohenfellner K, Hunley TE, Brezinska R, et al. ACE I/D gene polymorphism predicts renal damage in congenital uropathies. Pediatr Nephrol 1999; 13:514-518. (Pubitemid 29348708)
11. Hohenfellner K, Wingen AM, Nauroth O, et al. Impact of ACE I/D gene polymorphism on congenital renal malformations. Pediatr Nephrol 2001; 16:356-361. (Pubitemid 32366671)
12. Erdogan H, Mir S, Serdaroglu E, et al. Is ACE gene polymorphism a risk factor for renal scarring with low-grade reflux? Pediatr Nephrol 2004; 19:734-737.
13. Pardo R, Malaga S, Coto E, et al. Renin-angiotensin system polymorphisms and renal scarring. Pediatr Nephrol 2003; 18:110-114. (Pubitemid 41490296)
14. El-Sherbiny MT, Mousa OM, Shokeir AA, et al. Role of urinary transforming growth factor-beta1 concentration in the diagnosis of upper urinary tract obstruction in children. J Urol 2002; 168:1798-1800.
15. Furness PD 3rd, Maizels M, Han SW, et al. Elevated bladder urine concentration of transforming growth factor-beta1 correlates with upper urinary tract obstruction in children. J Urol 1999; 162:1033-1036.
16. Grandaliano G, Gesualdo L, Bartoli F, et al. MCP-1 and EGF renal expression and urine excretion in human congenital obstructive nephropathy. Kidney Int 2000; 58:182-192. (Pubitemid 30429863)
17. Taha MA, Shokeir AA, Osman HG, et al. Diagnosis of ureteropelvic junction obstruction in children: role of endothelin-1 in voided urine. Urology 2007; 69:560-564; discussion 564-565.
18. Taha MA, Shokeir AA, Osman HG, et al. Obstructed versus dilated non-obstructed kidneys in children with congenital ureteropelvic junction narrowing: role of urinary tubular enzymes. J Urol 2007; 178:640-646.
19. Carr MC, Peters CA, Retik AB, et al. Urinary levels of the renal tubular enzyme N-acetyl-beta-D-glucosaminidase in unilateral obstructive uropathy. J Urol 1994; 151:442-445.
20. Chromek M, Tullus K, Hertting O, et al. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinases-1 in acute pyelonephritis and renal scarring. Pediatr Res 2003; 53:698-705. (Pubitemid 36406743)
21. Galanakis E, Bitsori M, Dimitriou H, et al. Urine interleukin-8 as a marker of vesicoureteral reflux in infants. Pediatrics 2006; 117:e863-e867. (Pubitemid 46071353)
22. Everaert K, Delanghe J, Vande Wiele C, et al. Urinary alpha 1-microglobulin detects uropathy. A prospective study in 483 urological patients. Clin Chem Lab Med 1998; 36:309-315.
23. Artifoni L, Negrisolo S, Montini G, et al. Interleukin-8 and CXCR1 receptor functional polymorphisms and susceptibility to acute pyelonephritis. J Urol 2007; 177:1102-1106. (Pubitemid 46216366)
24. Kobayashi H, Miyakita H, Yamataka A, et al. Serum basic fibroblast growth factor as a marker of reflux nephropathy. J Pediatr Surg 2004; 39:1853-1855. (Pubitemid 40017736)
25. Sabasinska A, Zoch-Zwierz W, Wasilewska A, et al. Laminin and transforming growth factor beta-1 in children with vesicoureteric reflux. Pediatr Nephrol 2008; 23:769-774.
26. Kaneyama K, Kobayashi H, Yamataka A, et al. Serum soluble vascular cell adhesion molecule-1 (VCAM-1) concentrations in children with reflux nephropathy. Pediatr Surg Int 2005; 21:39-42. (Pubitemid 40169457)
27. Leroy S, Adamsbaum C, Marc E, et al. Procalcitonin as a predictor of vesicoureteral reflux in children with a first febrile urinary tract infection. Pediatrics 2005; 115:e706-e709. (Pubitemid 43843144)
28. Benador N, Siegrist CA, Gendrel D, et al. Procalcitonin is a marker of severity of renal lesions in pyelonephritis. Pediatrics 1998; 102:1422-1425. (Pubitemid 28550836)
29. Vaidya VS, Waikar SS, Ferguson MA, et al. Urinary biomarkers for sensitive and specific detection of acute kidney injury in humans. Clin Translat Sci 2008; 1:200-208. This study demonstrates the capability of multiplexed biomarkers for detecting AKI.
30. Orchard S, Hermjakob H, Julian RK Jr, et al. Common interchange standards for proteomics data: public availability of tools and schema. Proteomics 2004; 4:490-491. (Pubitemid 38235268)
31. Lescuyer P, Hochstrasser D, Rabilloud T. How shall we use the proteomics toolbox for biomarker discovery? J Proteome Res 2007; 6:3371-3376.
32. Howard BA, Wang MZ, Campa MJ, et al. Identification and validation of a potential lung cancer serum biomarker detected by matrix-assisted laser desorption/ionization-time of flight spectra analysis. Proteomics 2003; 3:1720-1724.
33. Anderson L, Hunter CL. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol Cell Proteom 2006; 5:573-588.
34. Lee RS, Monigatti F, Briscoe AC, et al. Optimizing sample handling for urinary proteomics. J Proteome Res 2008; 7:4022-4030. This study examined the effect of various clinical variables on the urinary proteome using label-free quantitative proteomic techniques.
35. Adachi J, Kumar C, Zhang Y, et al. The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins. Genome Biol 2006; 7:R80. (Pubitemid 44614864)
36. Sun W, Li F, Wu S, et al. Human urine proteome analysis by three separation approaches. Proteomics 2005; 5:4994-5001. (Pubitemid 43016918)
37. Thongboonkerd V. Practical points in urinary proteomics. J Proteome Res 2007; 6:3881-3890.
38. Yamamoto T, Langham RG, Ronco P, et al. Towards standard protocols and guidelines for urine proteomics: a report on the Human Kidney and Urine Proteome Project (HKUPP) symposium and workshop, 6 October 2007, Seoul, Korea and 1 November 2007, San Francisco, CA, USA. Proteomics 2008; 8:2156-2159.
39. O'Riordan E, Orlova TN, Podust VN, et al. Characterization of urinary peptide biomarkers of acute rejection in renal allografts. Am J Transplant 2007; 7:930-940. (Pubitemid 46481208)
40. Clarke W, Silverman BC, Zhang Z, et al. Characterization of renal allograft rejection by urinary proteomic analysis. Ann Surg 2003; 237:660-664; discussion 664-665. (Pubitemid 38174532)
41. Haubitz M, Wittke S, Weissinger EM, et al. Urine protein patterns can serve as diagnostic tools in patients with IgA nephropathy. Kidney Int 2005; 67:2313-2320. (Pubitemid 41623391)
42. Schiffer E, Mischak H, Novak J. High resolution proteome/peptidome analysis of body fluids by capillary electrophoresis coupled with MS. Proteomics 2006; 6:5615-5627. (Pubitemid 44683225)
43. Weissinger EM, Wittke S, Kaiser T, et al. Proteomic patterns established with capillary electrophoresis and mass spectrometry for diagnostic purposes. Kidney Int 2004; 65:2426-2434. (Pubitemid 38670029)
44. Smalley DM, Sheman NE, Nelson K, et al. Isolation and identification of potential urinary microparticle biomarkers of bladder cancer. J Proteome Res 2008; 7:2088-2096.
45. Saito M, Kimoto M, Araki T, et al. Proteome analysis of gelatin-bound urinary proteins from patients with bladder cancers. Eur Urol 2005; 48:865-871. (Pubitemid 41495397)
46. Irmak S, Tilki D, Heukeshoven J, et al. Stage-dependent increase of orosomucoid and zinc-alpha2-glycoprotein in urinary bladder cancer. Proteomics 2005; 5:4296-4304. (Pubitemid 41626097)
47. Celis JE, Gromova I, Moreira JM, et al. Impact of proteomics on bladder cancer research. Pharmacogenomics 2004; 5:381-394. (Pubitemid 38923652)
48. Lee RS, Monigatti F, Lutchman M, et al. Temporal variations of the postnatal rat urinary proteome as a reflection of systemic maturation. Proteomics 2008; 8:1097-1112. This is the first study to demonstrate that the normal urinary proteome varies with age.
49. Decramer S, Wittke S, Mischak H, et al. Predicting the clinical outcome of congenital unilateral ureteropelvic junction obstruction in newborn by urinary proteome analysis. Nat Med 2006; 12:398-400.